Search
Search
Rishi P. Singh, MD
Show Description +
Rishi P. Singh, MD, explains how particular timepoints in the HAWK and HARRIER trials allow researchers to understand the relationship between detectable disease activity and treatment with aflibercept (Eylea, Regeneron) or brolucizumab (Beovu, Novartis) in patients with wet AMD. Dr. Singh distills information from this post hoc analysis by explaining the practical implications for these study findings.
Posted: 5/13/2020
Rishi P. Singh, MD
Rishi P. Singh, MD, explains how particular timepoints in the HAWK and HARRIER trials allow researchers to understand the relationship between detectable disease activity and treatment with aflibercept (Eylea, Regeneron) or brolucizumab (Beovu, Novartis) in patients with wet AMD. Dr. Singh distills information from this post hoc analysis by explaining the practical implications for these study findings.
Posted: 5/13/2020
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ARVO: 2020.
Please log in to leave a comment.